Satellos Bioscience Inc ICOTF

QUICK SUMMARY

[db2067]

QUICK SUMMARY It all adds up for me, just a waiting game now for big news - market cap is so low here compared to equivalent peers that a balance-up share price to $0.25 - $0.30 makes sense see:

"Adalimumab (Humira) sells about $14 Billion / year in the US alone. Our Bertilimumab was developed by the same Nobel Winning Scientists at Cambridge Antibody that developed Humira. Our Bert has successfully passed Phase I and Phase II Trials in Bullous Pemphigoid and had FDA Orphan Drug and Fast Track Status." User ID: Rootbound

Co-008 and iCo Amp B have huge potential The joint development with Skymount is big with their access to Deep Drug AI iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical https://www.newsfilecorp.com/release/71207/iCo-Therapeutics-Announces-Joint-Development-of-iCo019-with-Skymount-Medical

https://www.lsu.edu/research/news/2020/0605-deepdrug.php “DeepDrug has the power to perform 15 years of drug discovery and due diligence in 15 days and leads the pack in medical AI in terms of accuracy, speed, and performance.”—Zubin Kothawala, Skymount Medical

https://skymountmed.com/deep-drug/
https://skymountmed.com/covid/

Comapre the teams https://skymountmed.com/about/ https://icotherapeutics.website/our-team/

Dr. Kishor Wasan and Dr. Peter Hnik on both - kind of a big deal. Both of iCo's drugs look pretty good to me, it has been a long time coming... plus a covid opportunity as well

iCo-008
Fast Track designation was recently granted for iCo-008 use in bullous pemphigoid (BP) by the US Food and Drug Administration (FDA). The FDA has also recently granted orphan drug designation to iCo-008 for the treatment of bullous pemphigoid.

iCo Amp B
Amphotericin B (Amp B) has been a gold standard for highly efficacious treatment of systemic fungal and parasitic infections with more than a 50-year history of intravenous (IV) formulations, yet no oral formulations are currently commercially available. The oral Amp B formulation developed by iCo Therapeutics may have significant advantages over an IV formulation with fewer adverse events and an easier way of administration. Assuming that clinical studies will confirm good safety and efficacy results, the oral Amphotericin B could be used in a variety of indications, including prevention of fungal infections in immunocompromised patients.

Historically, the main advantage of Amp B has been lower frequency of interaction with other drugs and a chance of developing drug-resistance to fungal infections. The early stages of the oral iCo Amp B program involved various formulations of Amp B used in nonclinical models of aspergillosis and candidiasis as well as leishmaniasis. All studies showed good efficacy and safety of the oral Amp B formulations, and the compound selected for further clinical development in capsule form is referred to as iCo-019.